Global Genomics Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

Genomics Market Size

• The global Genomics market was valued at USD 42.73 billion in 2024 and is expected to reach USD 143.73 billion by 2032
• During the forecast period of 2025 to 2032 the market is likely to grow at a CAGR of 16.37%, primarily driven by advancements in gene editing technologies
• This growth is driven by factors such as the increasing prevalence of chronic diseases, declining sequencing costs, and expanding applications of genomics in diagnostics

Genomics Market Analysis

• The global genomics market encompasses a wide range of technologies and services used to analyse and manipulate genetic material, playing a crucial role in areas such as diagnostics, drug discovery, personalized medicine, and agricultural biotechnology
• The demand is significantly driven by increasing investments in genomics research, a growing focus on precision medicine, and the rising burden of chronic and genetic diseases. The declining cost of genome sequencing has further accelerated adoption across both clinical and research settings
• North America stands out as a leading region in the genomics market, supported by strong research funding, robust healthcare infrastructure, and a high concentration of key industry players and academic institutions 
• For instance, the U.S. has seen a surge in genomic testing and research initiatives, with government programs such as the NIH’s All of Us Research Program promoting large-scale genomic data collection and utilization
• Globally, genomics technologies are considered one of the most transformative innovations in modern healthcare and life sciences, offering unprecedented opportunities for early disease detection, targeted therapy, and improved patient outcomes

Report Scope and Genomics Market Segmentation  

Genomics Market Trends

“Integration of Artificial Intelligence and Big Data Analytics”

• One prominent trend in the global genomics market is the increasing integration of artificial intelligence (AI) and big data analytics to enhance genomic data interpretation and accelerate research outcomes
• These technologies enable the rapid analysis of vast genomic datasets, uncovering complex patterns and genetic variations that would be difficult to detect manually 
• For instance, AI-powered tools are being used to predict disease risks, identify therapeutic targets, and streamline the development of personalized treatment plans by analyzing patient-specific genomic profiles
• Big data platforms also facilitate collaborative research by enabling real-time sharing and analysis of genomic information across institutions and geographies
• This trend is transforming genomics into a more precise, predictive, and scalable science, significantly boosting its applications in healthcare, biotechnology, and pharmaceutical research

Genomics Market Dynamics

Driver

“Rising Demand for Precision Medicine and Early Disease Detection”

• The increasing global focus on precision medicine and early disease detection is a major driver for the growth of the genomics market. Genomics enables the identification of genetic predispositions, helping to tailor treatment plans based on an individual’s unique genetic profile
• As chronic and genetic diseases such as cancer, cardiovascular disorders, and rare inherited conditions become more prevalent, the need for early and accurate diagnostics has intensified, boosting the demand for genomic technologies
• Genomic sequencing and analysis offer significant advantages in detecting disease markers before clinical symptoms emerge, allowing for timely intervention and improved treatment outcomes
• The Healthcare systems and pharmaceutical companies are increasingly leveraging genomic data to develop targeted therapies, thereby enhancing the effectiveness of treatments and minimizing side effects
• As the global healthcare landscape shifts towards preventive and personalized approaches, genomics is becoming indispensable in shaping next-generation healthcare solutions

For instance,

• In March 2022, the National Human Genome Research Institute (NHGRI) emphasized the role of genomics in advancing precision medicine, noting that genomic data is central to predicting disease risk, optimizing therapies, and understanding individual responses to medications
• In April 2021, the World Health Organization launched its Global Genomic Surveillance Strategy, underscoring the importance of genomics in early detection and control of infectious diseases, such as COVID-19, further driving the integration of genomics in public health efforts 
• As a result, the rising emphasis on precision medicine and proactive healthcare is significantly fueling the adoption of genomics, positioning it as a core driver of growth in the global market

Opportunity

“Unlocking Genomic Insights with Artificial Intelligence Integration”

• The integration of artificial intelligence (AI) in genomics is creating transformative opportunities by accelerating data analysis, improving diagnostic accuracy, and enabling real-time interpretation of complex genomic information
• AI algorithms can analyze massive genomic datasets to identify patterns, mutations, and gene-disease associations far more efficiently than traditional methods, significantly enhancing the speed and precision of research and clinical decision-making
• In addition, AI-driven platforms are helping predict disease risks, recommend personalized treatment plans, and optimize drug discovery by modeling genetic responses to therapies

For instance,

• In June 2024, according to an article published in Nature Biotechnology, deep learning models have been successfully used to predict cancer progression by analyzing whole genome sequencing data, enabling clinicians to make earlier and more informed treatment decisions
• In August 2023, according to research from the Broad Institute and Google Health, AI tools demonstrated superior accuracy in identifying rare genetic disorders from facial and genomic data, showcasing AI’s role in improving diagnostics for hard-to-diagnose conditions 
• By enabling faster, more accurate analysis and personalized insights, AI is unlocking new possibilities in genomics research, diagnostics, and therapeutics—ultimately contributing to improved patient care and shaping the future of precision medicine

Restraint/Challenge

“High Costs of Genomic Technologies Limiting Widespread Adoption”

• The high cost of genomic sequencing technologies and data analysis tools remains a significant barrier to widespread adoption, particularly in low- and middle-income countries
• Despite declining costs over the years, comprehensive genome sequencing and interpretation still require substantial investments in advanced equipment, bioinformatics infrastructure, and skilled personnel
• This financial burden can prevent smaller research institutions, hospitals, and clinics from fully integrating genomic solutions into routine care or research initiatives

For instance,

• In October 2023, according to a report by Global Genomics Alliance, the cost of whole genome sequencing, including data storage and interpretation, can still exceed USD 1,000 per individual, making it unaffordable for large-scale population studies in developing regions
• In December 2022, an article published in The Lancet Digital Health highlighted that limited funding and high operational costs hinder the implementation of genomics-based diagnostics in public healthcare systems, especially in countries with constrained health budgets 
• Consequently, the high costs associated with genomic technologies contribute to disparities in access and slow down the global expansion of genomics in healthcare, posing a challenge to market growth despite its immense potential

Genomics Market Scope

The market is segmented on the basis of deliverables, technology, process, application, and end user.

Genomics Market Regional Analysis

“North America is the Dominant Region in the Genomics Market”

• North America leads the global genomics market, supported by robust research infrastructure, substantial government funding, and a high concentration of biotechnology and pharmaceutical companies
• U.S. accounts for a significant market share due to initiatives such as the Precision Medicine Program, rising adoption of genomic testing in clinical settings, and widespread use of next-generation sequencing technologies in healthcare and research
• The strong collaborations between academic institutions, research organizations, and private enterprises, along with favorable reimbursement policies for genetic testing, further bolster the regional market
• In addition, the presence of key market players and continuous innovation in areas such as AI-driven genomics and CRISPR-based gene editing significantly enhance the market outlook across North America

“Asia-Pacific is Projected to Register the Highest Growth Rate”

• Asia-Pacific is expected to experience the fastest growth in the genomics market, fueled by increasing investments in healthcare infrastructure, expanding genomics research initiatives, and rising prevalence of chronic and genetic diseases
• Countries such as China, India, Japan, and South Korea are emerging as genomic innovation hubs, with growing government support and increased focus on precision medicine and population-wide genome sequencing projects
• Japan remains a technologically advanced market with strong research capabilities and early adoption of cutting-edge genomic tools in clinical practice
• China and India are seeing rapid growth due to their large populations, increased public and private investments in biotech sectors, and rising awareness of the benefits of genetic testing for disease prevention and treatment.

Genomics Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

The Major Market Leaders Operating in the Market Are:

• Illumina, Inc. (U.S.)
• Thermo Fisher Scientific Inc. (U.S.)
• QIAGEN (Germany)
• Agilent Technologies (U.S.)
• F. Hoffmann-La Roche Ltd (Switzerland)
• Bio-Rad Laboratories, Inc. (U.S.)
• PacBio (U.S.)
• Oxford Nanopore Technologies plc (U.K.)
• BGI (China)
• 10x Genomics. (U.S.)
• Eurofins Scientific (Luxembourg)
• Myriad Genetics, Inc. (U.S.)
• GENEWIZ from Azenta Life Sciences (U.S.)
• Color Health, Inc. (U.S.)
• Strand (India)
• CD Genomics (U.S.)
• PierianDx (U.S.)
• Genuity Science (Ireland)
• Personalis, Inc. (U.S.)
• Natera, Inc. (U.S.)

Latest Developments in Global Genomics Market

• In March 2025, Illumina Inc. launched its next-generation NovaSeq X Plus sequencing platform in key global markets, offering enhanced throughput, reduced sequencing costs, and integrated AI-powered analytics to accelerate whole genome sequencing applications in clinical and research settings
• In February 2025, the UK government announced a major expansion of its Genomics England program, aiming to sequence an additional 1 million genomes over the next five years to advance rare disease diagnosis, cancer research, and personalized healthcare initiatives
• In January 2025, Thermo Fisher Scientific introduced its Ion Torrent Genexus Dx Integrated Sequencer, a fully automated NGS platform designed for clinical diagnostic use, enabling same-day results and simplifying genomic workflows for oncology and infectious disease applications
• In November 2024, BGI Genomics partnered with the Indian Council of Medical Research (ICMR) to establish a nationwide genomic surveillance program targeting antimicrobial resistance and genetic disorders, marking a significant step toward public health preparedness and precision medicine in India
• In October 2024, CRISPR Therapeutics and Vertex Pharmaceuticals received expanded FDA approval for their gene-editing therapy, Casgevy, for treating additional beta-thalassemia genotypes, reinforcing the role of genomics in advanced therapeutic solutions and personalized treatment approaches

SKU-14489